These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Coronary thrombolysis: nonmortality measures of efficacy.
    Author: Belenkie I.
    Journal: Can J Cardiol; 1993; 9(6):499-504. PubMed ID: 8221343.
    Abstract:
    Early reperfusion during AMI results in myocardial salvage, recovery of function and reduced mortality (level I). This can be achieved with all of the currently available thrombolytic agents (level I). Benefits from late reperfusion are not proven but there are data which suggest that delayed reperfusion is better than persistent occlusion (level II). There is now clear evidence that accelerated dose rt-PA (plus heparin) is more effective in reducing mortality than is SK (plus heparin) or a combined regimen of rt-PA/SK (plus heparin) (level I). Soon-to-be published data will refine the extent to which different subgroups benefit and will provide a basis from which to select the most appropriate agent in individual patients. The overall benefit was the reduction of one death per 100 patients treated with rt-PA compared with SK, while the absolute benefit varied considerably among patient subgroups.
    [Abstract] [Full Text] [Related] [New Search]